American Journal of Cardiovascular Drugs

, Volume 10, Issue 3, pp 203–208

Acute Effects of Isosorbide Dinitrate and Nicorandil on the Coronary Slow Flow Phenomenon

  • Kenji Sadamatsu
  • Hideki Tashiro
  • Keiki Yoshida
  • Tomoki Shikada
  • Kenso Iwamoto
  • Kunio Morishige
  • Yuya Yoshidomi
  • Tomotake Tokunou
  • Haruki Tanaka
Original Research Article

Abstract

Background

Microvascular dysfunction has been proposed as the most likely mechanism of the coronary slow flow phenomenon (CSFP).

Objective

To determine the effects of isosorbide dinitrate and nicorandil on the CSFP.

Methods

Changes in thrombolysis in myocardial infarction (TIMI) frame count following the intracoronary administration of isosorbide dinitrate and nicorandil were assessed in 11 patients with the CSFP.

Results

After the administration of isosorbide dinitrate, the median TIMI frame count decreased to 32 (range 20–60) [p = 0.003], which was lower than that of the control [43 (29–73)]. The count decreased further to 25 (12–34) [p = 0.041] after the administration of nicorandil. The count after the subsequent administration of contrast medium was increased to 32 (20–49) [p = 0.03].

Conclusions

These angiographic findings indicate that the intracoronary administration of nicorandil is superior to isosorbide dinitrate with regard to improving the CSFP. These findings suggest that micro-vascular spasm is the main factor in the pathogenesis of the CSFP.

References

  1. 1.
    Tambe AA, Demany MA, Zimmerman HA, et al. Angina pectoris and slow flow velocity of dye in coronary arteries: a new angiographic finding. Am Heart J 1972;84:66–71.PubMedCrossRefGoogle Scholar
  2. 2.
    Goel PK, Gupta SK, Agarwal A, et al. Slow coronary flow: a distinct angiographic subgroup in syndrome X. Angiology 2001; 52: 507–14.PubMedCrossRefGoogle Scholar
  3. 3.
    Beltrame JF, Limaye SB, Horowitz JD. The coronary slow flow phenomenon: a new coronary microvascular disorder. Cardiology 2002; 97: 197–202.PubMedCrossRefGoogle Scholar
  4. 4.
    Sadamatsu K, Shikada T, Nagaoka K, et al. Coronary flow was not fully delayed at the first administration of contrast in patients with coronary slow flow phenomenon [abstract]. Atherosclerosis 2008 Suppl.; 9: 216.Google Scholar
  5. 5.
    Mangieri E, Macchiarelli G, Ciavolella M, et al. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn 1996; 37: 375–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Beltrame JF, Limaye SB, Wuttke RD, et al. Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. Am Heart J 2003; 146: 84–90.PubMedCrossRefGoogle Scholar
  7. 7.
    Erdogan D, Caliskan M, Gullu H, et al. Coronary flow reserve is impaired in patients with slow coronary flow. Atherosclerosis 2003; 191: 168–74.CrossRefGoogle Scholar
  8. 8.
    Fineschi M, Bravi A, Gori T. The “slow coronary flow” phenomenon: evidence of preserved coronary flow reserve despite increased resting microvascular resistances. Int J Cardiol 2008; 127: 358–61.PubMedCrossRefGoogle Scholar
  9. 9.
    Li J-J, Xu B, Li Z-C, et al. Is slow coronary flow associated with inflammation? Med Hypotheses 2006; 66: 504–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Leone MC, Gori T, Fineschi M. The coronary slow flow phenomenon: a new cardiac “Y” syndrome? Clin Hemorheol Microcirc 2008; 39: 185–90.PubMedGoogle Scholar
  11. 11.
    Sadamatsu K, Inoue S, Tashiro H. Coronary slow flow phenomenon caused by contrast-induced microvascular spasm. Intern Med 2007; 46: 1991–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Simpson D, Wellington K. Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients. Drugs 2004; 64: 1941–55.PubMedCrossRefGoogle Scholar
  13. 13.
    Beltrame JF, Turner SP, Leslie SL, et al. The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon. J Am Coll Cardiol 2004; 44: 57–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Gibson CM, Schömig A. Coronary and myocardial angiography: angiographic assessment of both epicardial and myocardial perfusion. Circulation 2004; 109: 3096–105.PubMedCrossRefGoogle Scholar
  15. 15.
    Hongo M, Takenaka H, Uchikawa S, et al. Coronary microvascular response to intracoronary administration of nicorandil. Am J Cardiol 1995; 75: 246–50.PubMedCrossRefGoogle Scholar
  16. 16.
    Jones CJ, Kuo L, Davis MJ, et al. In vivo and in vitro vasoactive reactions of coronary arteriolar microvessels to nitroglycerin. Am J Physiol 1996; 271: H461–8.PubMedGoogle Scholar
  17. 17.
    Yamada T, Okamoto M, Sueda T, et al. Response of conductance and resistance vessels of the coronary artery to intracoronary isosorbide dinitrate in patients with variant angina. Intern Med 1996; 35: 844–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Sun H, Fukumoto Y, Ito A, et al. Coronary microvascular dysfunction in patients with microvascular angina: analysis by TIMI frame count. J Cardiovasc Pharmacol 2005; 46: 622–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Vijayalakshmi K, Kunadian B, Whittaker VJ, et al. Impact of catheter sizes and intracoronary glyceryl trinitrate on the TIMI frame count when digital angiograms are acquired at lower frame rates during elective angiography and PCI. Acute Card Care 2007; 9: 231–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Mangieri E, Tanzilli G, De Vincentis G, et al. Slow coronary flow and stress myocardial perfusion imaging: different patterns in acute patients. J Cardiovasc Med (Hagerstown) 2006; 7: 322–7.CrossRefGoogle Scholar
  21. 21.
    Fraggaso G, Chierchia SL, Arioli F, et al. Coronary slow-flow causing transient myocardial hypoperfusion in patients with cardiac syndrome X: long-term clinical and functional prognosis. Int J Cardiol 2009; 137: 137–44.CrossRefGoogle Scholar
  22. 22.
    Saya S, Hennebry TA, Lozano P, et al. Coronary slow flow phenomenon and risk for sudden cardiac death due to ventricular arrhythmias. Clin Cardiol 2008; 31: 352–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Demirkol MO, Yaymaci B, Mutlu B. Dipyridamole myocardial perfusion single photon emission computed tomography in patients with slow coronary flow. Coron Artery Dis 2002; 13: 223–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Kurtoglu N, Akcay A, Dindar I. Usefulness of oral dipyridamole therapy for angiographic slow coronary artery flow. Am J Cardiol 2001; 87: 777–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Ikeda N, Yasu T, Kubo N, et al. Nicorandil versus isosorbide dinitrate as adjunctive treatment to direct balloon angioplasty in acute myocardial infarction. Heart 2004; 90: 181–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Hayashi T, Ichikawa M, Iwata A, et al. Intracoronary nicorandil relieves multiple coronary vasospasm with hemodynamic collapse. Circ J 2008; 72: 327–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Kurisu S, Inoue I, Kawagoe T, et al. Intracoronary administration of nicorandil for the treatment of spontaneous microvascular spasm with ST segment elevation. Circ J 2004; 68: 267–9.CrossRefGoogle Scholar
  28. 28.
    IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359: 1269–75.CrossRefGoogle Scholar
  29. 29.
    Celebi H, Catakoglu AB, Kurtoglu H, et al. The relation between coronary flow rate, plasma endothelin-1 concentrations, and clinical characteristics in patients with normal coronary arteries. Cardiovasc Revasc Med 2008; 9: 144–8.PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Kenji Sadamatsu
    • 1
    • 2
  • Hideki Tashiro
    • 2
  • Keiki Yoshida
    • 1
  • Tomoki Shikada
    • 2
  • Kenso Iwamoto
    • 2
  • Kunio Morishige
    • 2
  • Yuya Yoshidomi
    • 1
  • Tomotake Tokunou
    • 1
  • Haruki Tanaka
    • 1
  1. 1.Department of CardiologySaga Prefectural Hospital KoseikanSagaJapan
  2. 2.Department of CardiologySt Mary’s HospitalKurumeJapan

Personalised recommendations